Thomas Steyer’s Travere Therapeutics TVTX Stock Holding History

Thomas Steyer’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-12,000	Closed	-$357K	–	180
2026 Q1	$357K	Hold	12,000	–	–	﹤0.01%	113
2025 Q4	$459K	Hold	12,000	–	–	﹤0.01%	97
2025 Q3	$287K	Hold	12,000	–	–	﹤0.01%	105
2025 Q2	$178K	Buy	+12,000	New	+$199K	﹤0.01%	124
2024 Q1	–	Sell	-1,094,000	Closed	-$9.84M	–	187
2023 Q4	$9.84M	Buy	1,094,000 +822,483	+303%	+$5.99M	0.05%	81
2023 Q3	$2.43M	Buy	+271,517	New	+$3.83M	0.01%	106

Other funds holding TVTX

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Thomas Steyer's TVTX Position: Q2 2026 in Review

Thomas Steyer sold out of Travere Therapeutics (TVTX) in Q2 2026, closing a stake of 12,000 shares — an estimated $357K sold.

Thomas Steyer first reported a position in TVTX in Q3 2023 and held it in 6 quarters. The position peaked at $9.84M in Q4 2023. 317 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

Thomas Steyer reported no remaining Travere Therapeutics position as of Q2 2026 after selling out during the quarter.
Thomas Steyer sold 12,000 Travere Therapeutics shares in Q2 2026, an estimated $357K.
Thomas Steyer first reported a position in Travere Therapeutics in Q3 2023 and held it in 6 quarters.
Thomas Steyer's Travere Therapeutics position peaked at $9.84M in Q4 2023.
317 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Farallon Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.